<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110014</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00048919.sub</org_study_id>
    <secondary_id>R01CA218416</secondary_id>
    <nct_id>NCT05110014</nct_id>
  </id_info>
  <brief_title>Substudy of Protocol NCT03843957 - Effect of mPATH on Screening for Depression, Fall Risk, and Safety</brief_title>
  <official_title>Substudy of Protocol NCT03843957: Effect of mPATH on Screening for Depression, Fall Risk, and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a sub-study for data analysis of data collected as part of the larger randomized&#xD;
      controlled trial &quot;Effectiveness and Implementation of mPATH-CRC&quot; (NCT03843957) to determine&#xD;
      if self-administered screening with an iPad increases the detection of patients with&#xD;
      depression, falls, and intimate partner violence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As part of the parent study (NCT0343957), investigators developed an iPad program called&#xD;
      mPATH that patients use at their primary care clinician's office to encourage colorectal&#xD;
      cancer screening. To encourage practices to use mPATH with every patient, the investigators&#xD;
      included in the program the health system's required screening items for depression, fall&#xD;
      risk, and intimate partner violence, thereby offloading this routine task from clinical&#xD;
      staff. It is possible that mPATH will increase detection of depression, fall risk, and&#xD;
      intimate partner violence because: 1) mPATH systematically asks these screening items of all&#xD;
      patients, and 2) patients may feel more comfortable answering these items on an iPad survey&#xD;
      than during an in-person interview.&#xD;
&#xD;
      To determine the effect of mPATH on the performance of this screening, investigators will&#xD;
      examine a limited use dataset comparing the 2 months before a clinic started using mPATH to&#xD;
      the 2 months after the clinic began using mPATH. Because clinics may need some time to fully&#xD;
      adopt mPATH, investigators will exclude the first two weeks following the launch of mPATH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Actual">February 27, 2020</completion_date>
  <primary_completion_date type="Actual">February 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Screening Positive for Depression, Fall Risk or Intimate Partner Violence - Pre mPATH Use</measure>
    <time_frame>2 months prior to use of intervention</time_frame>
    <description>The primary outcome will be the proportion of patients seen in each time period (&quot;pre&quot; vs. &quot;post&quot;) who screen positive for depression, fall risk, or intimate partner violence. The &quot;pre&quot; time period will be Days -60 to -1 (the 60 day period before mPATH Launch). Screening positive for depression will be a score of 3 or greater on the Patient Health Questionnaire-2. Screening positive for fall risk will be answering &quot;yes&quot; to having a device to assist with mobility and/or having fallen in the last year. Screening positive for intimate partner violence will be answering yes to any of the health system's three questions about safety in the home.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants Screening Positive for Depression, Fall Risk or Intimate Partner Violence - Post mPATH Use</measure>
    <time_frame>2 months after use of intervention</time_frame>
    <description>The primary outcome will be the proportion of patients seen in each time period (&quot;pre&quot; vs. &quot;post&quot;) who screen positive for depression, fall risk, or intimate partner violence. The &quot;post&quot; time period will be days 14 to 73 (the 60 day period commencing 2 weeks after mPATH Launch). Screening positive for depression will be a score of 3 or greater on the Patient Health Questionnaire-2. Screening positive for fall risk will be answering &quot;yes&quot; to having a device to assist with mobility and/or having fallen in the last year. Screening positive for intimate partner violence will be answering yes to any of the health system's three questions about safety in the home.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Screening Positive for Depression Using Patient Health Questionnaires (PHQ-2 score of 3 or greater)</measure>
    <time_frame>2 months before and 2 months after using intervention</time_frame>
    <description>The PHQ-2 inquires about the frequency of depressed mood and anhedonia over the past two weeks. Screen positive for depression using the PHQ-2 items. PHQ-2 score obtained by adding score for each question (total points). A PHQ-2 score ranges from 0-6. If the score is 3 or greater, major depressive disorder is likely.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Screening Positive for Moderately Severe or Severe Depression Using Patient Health Questionnaires (PHQ-9 score greater than 14)</measure>
    <time_frame>2 months before and 2 months after using intervention</time_frame>
    <description>The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ-9 score obtained by adding score for each question (total points). Total scores of 5, 10, 15, and 20 represent cut points for mild, moderate, moderately severe and severe depression, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Screening Positive for Severe Depression Using Patient Health Questionnaires (PHQ-9 score greater than 19)</measure>
    <time_frame>2 months before and 2 months after using intervention</time_frame>
    <description>The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ-9 score obtained by adding score for each question (total points). Total scores of 5, 10, 15, and 20 represent cut points for mild, moderate, moderately severe and severe depression, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with a Patient Health Questionnaires (PHQ-9 score greater than 14) and not Currently Taking a Medication for Depression.</measure>
    <time_frame>2 months before and 2 months after using intervention</time_frame>
    <description>The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ-9 score obtained by adding score for each question (total points). Total scores of 5, 10, 15, and 20 represent cut points for mild, moderate, moderately severe and severe depression, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Report Thoughts of Self Harm - Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>2 months before and 2 months after using intervention</time_frame>
    <description>This is measured by the screening question on suicide risk on the PHQ-9: &quot;Thoughts that you would be better off dead or of hurting yourself in some way.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Screening Positive for Fall Risk at Home</measure>
    <time_frame>2 months before and 2 months after using intervention</time_frame>
    <description>Screen positive for fall risk at home. In addition, the outcomes below will be assessed:&#xD;
Have fallen in last 6 months&#xD;
Have had a fall with injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Screening Positive for Intimate Partner Violence</measure>
    <time_frame>2 months before and 2 months after using intervention</time_frame>
    <description>Screen positive for safety concerns at home. In addition, the outcome below will be assessed:&#xD;
Report that conflicts turn into fights</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23026</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Primary Care Office Visits</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The limited use dataset will contain the following data elements for each completed patient visit:&#xD;
Date of clinic visit (where each date is indicated by a number relative to the clinic's Launch Date)&#xD;
Clinic (designated by a unique study clinic identifier)&#xD;
Type of visit completed (for example, new patient visit, return patient visit, annual exam)&#xD;
Patient age&#xD;
Patient gender&#xD;
Patient race/ethnicity&#xD;
Patient primary insurance&#xD;
Nursing staff who roomed the patient (designated by a unique study identifier)&#xD;
Whether patient used mPATH-CheckIn program (Y/N)&#xD;
Whether nursing staff used mPATH Nursing Module to transmit mPATH data to electronic health record (Y/N)&#xD;
Whether patient has a diagnosis of depression in the problem list in the EHR (Y/N)&#xD;
Whether patient has an antidepressant medication listed in the active medication list ( (Y/N)&#xD;
Results of depression screening items&#xD;
Results of fall risk screening items&#xD;
Results of safety at home screening items</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Primary Care Office Visits</intervention_name>
    <description>mPATH iPad program that contains self-administered screening items for depression, fall risk, and intimate partner violence</description>
    <arm_group_label>Primary Care Office Visits</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Completed a provider visit at the study clinic during the 60 days prior to the clinic&#xD;
             launching the mPATH program (the &quot;pre&quot; time period), or completed a provider visit at&#xD;
             the study clinic during days 14 - 73 after the launch of mPATH (the &quot;post&quot; time&#xD;
             period)&#xD;
&#xD;
          -  Have a preferred language of English or Spanish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Requiring a language interpreter for a language other than Spanish&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Miller, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest Baptist Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fall risk</keyword>
  <keyword>Intimate partner violence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

